Clinical trials: Positron Emission Tomography
Squamous Cell Carcinoma of the Oral, Clinically Node-Negative and Radiology
Predictive Value of PET CT in the Histologic Lymph Node Status of Patients With Squamous Cell Carcinoma of the Oral N0 Clinical and Radiological Cavity.
Squamous cell carcinoma of the VADS represents the majority of cancers in ENT. Metastatic lymph node involvement is an important prognostic factor.
- Trial name
- ORNICA (NCT03947892)
- Testing
- PET-CT
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Grenoble
Unspecified Adult Solid Tumor, Protocol Specific
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
This pilot clinical trial studies fluorine F 18 fluorothymidine (FLT)-positron emission tomography/magnetic resonance imaging (PET/MRI) in measuring early response in patients with metastatic solid tumors receiving treatment that…
- Trial name
- NCT02055586
- Testing
- fluorine F 18 fluorothymidine, positron emission tomography, magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
MRI Scans
Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging
This work seeks to develop, evaluate and use new MRI methods for non-invasive quantitative assessment of myocardial perfusion and perfusion reserve (MPR), and to compare with quantitative PET imaging.
- Trial name
- NCT02608944
- Testing
- Adenosine, Regadenoson, O-15 labeled radioactive water
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Utah
Neuroendocrine Tumors
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
The aim of this study is to evaluate the potential of Al18F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide (Al18F-NOTA-octreotide) as a positron emission tomography (PET) somatostatin receptor imaging agent in patients with…
- Trial name
- NCT03883776
- Testing
- Al18F-NOTA-octreotide, PET/CT, Venous blood samples
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Tumor, Positron-Emission Tomography
68Ga-BNU-PSMA PET/CT in Patients With Various Types of Cancer
To evaluate the potential usefulness of 68Ga-BNU-PSMA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer.
- Conditions
- Tumor, Positron-Emission Tomography, Metastasis
- Trial name
- NCT04525612
- Testing
- 68Ga-BNU-PSMA
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Autoimmune Disease, Crohn Disease
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases.
- Conditions
- Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis
- Trial name
- NCT02925351
- Testing
- Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer, Non-Small Cell Lung Cancer
PET CT Re-Planning NSCLC (4DCT-PET)
This study will see whether the addition of more frequent planning CTs during the course of radiation, and of Positron Emission Tomography (PET), a diagnostic test similar to CT, prior to and during a course of radiation may…
- Trial name
- NCT03403127
- Testing
- PET/CT Scans
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Malignant Neoplasm
18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions
This clinical trial studies 18F-clofarabine positron emission tomography (PET)/computed tomography (CT) in imaging patients with cancer before and after treatment with a therapy that activates the patient's immune system…
- Trial name
- NCT02888301
- Testing
- Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage…
- Trial name
- NCT00444223
- Testing
- fluorine F 18 FEQA + positron emission tomography
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy
RATIONALE: Measuring changes in glucose metabolism in patients with cancer may help doctors predict how patients respond to treatment.
- Trial name
- NCT00450567
- Testing
- computed tomography, positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Sarcoma
PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma
RATIONALE: Diagnostic procedures, such as PET scan and CT scan, may help doctors determine the extent of cancer and predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00335751
- Testing
- positron emission tomography computed tomography (PET/CT)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma, Glioma
Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma
This clinical trial studies how well delayed fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in improving visualization of brain tumors in patients with glioblastoma.
- Trial name
- NCT02919332
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NYSCT MM (NCT03506802)
- Testing
- 18F-FHBG, Aldesleukin, Cellular Therapy
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
- Trial name
- NCT00303901
- Testing
- cryosurgery, positron emission tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cervical Cancer, Uterine Cervical Cancer
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer
In this study, 50 evaluable patients will undergo one FDG-PET study during their chemoradiation, in addition to the standard of care pretreatment and 3-month post-treatment clinical FDG-PET/CT or FDG-PET/MR scans.
- Conditions
- Cervical Cancer, Uterine Cervical Cancer, Uterine Cervical Neoplasms
- Trial name
- NCT02317302
- Testing
- FDG-PET/MR, FDG-PET/CT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Stage II Adult Soft Tissue Sarcoma, Stage IIA Adult Soft Tissue Sarcoma
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
This pilot early phase I trial studies how well fluorothymidine F-18 positron emission tomography (PET) works in imaging patients with intermediate or high grade soft tissue sarcoma.
- Conditions
- Stage II Adult Soft Tissue Sarcoma, Stage IIA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
- Trial name
- NCT03613259
- Testing
- Fluorothymidine F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer, Recurrent Prostate Cancer
Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.
- Trial name
- NCT02531672
- Testing
- 11C-choline, PET/CT Scan
- Where
- 5 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Neoplasms, Lung Neoplasms
Imaging Study for FdCyd and THU Cancer Treatment
Background: The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body.
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT01479348
- Testing
- [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients
Describe strengths and limitations of FDG PET/CT for staging. Evaluate the utility of PET/CT in assessment of therapy response and restaging
- Trial name
- NCT04395651
- Testing
- PET/CT
- Volunteers
- 30 people
- Sponsor
- Assiut University
Nasopharyngeal Carcinoma
Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients
NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and high-sensitivity PET/CT protocol simultaneously in the follow-up of Locally Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT04394091
- Testing
- ultrasensitive PET CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University